Serina Therapeutics (SER) Consolidated Net Income (2018 - 2026)

Serina Therapeutics has reported Consolidated Net Income for 8 years, with the latest figure at -$6.4 million in Q4 2025.

• Quarterly Consolidated Net Income fell 7.95% year-over-year to -$6.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$25.0 million (down 33.03% YoY) and the FY2025 annual result came in at -$19.2 million, down 71.46% from the prior year.
• Consolidated Net Income grew to -$6.4 million in Q4 2025 per SER's latest filing, from -$6.4 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at $435000.0 in Q4 2023 and troughed at -$6.4 million in Q3 2025.
• A 5-year average of -$3.0 million and a median of -$2.6 million in 2022 frame the typical range for Consolidated Net Income.
• The sharpest annual moves came in 2022 and 2023: Consolidated Net Income plunged 37500.0% in 2022, then soared 124.41% in 2023.
• Over 5 years, Consolidated Net Income stood at -$7000.0 in 2021, then slumped by 25357.14% to -$1.8 million in 2022, then surged by 124.41% to $435000.0 in 2023, then plunged by 1458.39% to -$5.9 million in 2024, then fell by 7.95% to -$6.4 million in 2025.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$6.4 million, -$6.4 million, and -$6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.